Stereoselective behavioral effects of Lu 19-005 in monkeys: relation to binding at cocaine recognition sites.
S Rosenzweig-Lipson, J Bergman, R D Spealman, B K Madras
Index: Psychopharmacology 107(2-3) , 186-94, (1992)
Full Text: HTML
Abstract
The effects of the monoamine uptake inhibitor Lu 19-005 ((+/-)-trans-3-(3,4-dichlorophenyl)-N-methyl-1-indanamine) and its (+) and (-) enantiomers, Lu 20-042 and Lu 20-043, were compared with those of cocaine and the selective dopamine uptake inhibitor GBR 12909 (1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine) in behavioral and radioligand binding experiments. Behavioral experiments were conducted in groups of squirrel monkeys trained under fixed-interval schedules of reinforcement in which responding was maintained either by presentation of food or by termination of a visual stimulus associated with mild electric shock. Radioligand binding studies were conducted using [3H]CFT and [3H]GBR 12935 to label elements of the dopamine uptake system in caudate-putamen membranes of cynomolgus monkeys. All drugs produced dose-related increases in response rate under the fixed-interval schedules. Lu 19-005, Lu 20-042, and Lu 20-043 had relatively slow onsets (approximately 2 h) and relatively long durations of action, with effects persisting for two or more days following administration. Stereoselectivity was evident in the behavioral effects of the enantiomers of Lu 19-005, with Lu 20-042 being approximately 14 times more potent than Lu 20-043. In radioligand binding experiments, Lu 19-005 and its enantiomers were potent inhibitors of specifically bound [3H]CFT and [3H]GBR 12935. As in behavioral experiments, Lu 20-042 was more potent than Lu 20-043. The degree of stereoselectivity, however, varied with the temperature of the assay medium.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Compounds
Related Articles:
1999-10-01
[J. Pharmacol. Exp. Ther. 291 , 60-69, (1999)]
1985-05-01
[J. Neurochem. 44 , 1615-1622, (1985)]
1985-04-01
[Naunyn Schmiedebergs Arch. Pharmacol. 329 , 101-107, (1985)]
[J. Neural Transm. Gen. Sect. 64 , 227-238, (1985)]
1989-07-18
[Eur. J. Pharmacol. 166(2) , 251-60, (1989)]